Inhibitor Therapeutics INTI
OTC INTI
$0.08 +0.00 (+0.00%)
At close: Nov 10, 2026 · 4:00 PM EST

Inhibitor Therapeutics (INTI) Interest Expenses (2014 - 2022)

Updated

Inhibitor Therapeutics' Interest Expenses was $3,356 in Q4 2022, down 56.4% from the prior quarter.

Analysis

Inhibitor Therapeutics (INTI) Interest Expenses (2014 - 2022) Analysis & Trends

For FY2022, Interest Expenses at Inhibitor Therapeutics came in at $23,234, up 56.6% from FY2021.

  • In earlier years, Interest Expenses was $14,837 in FY2021.
  • The Q4 2022 figure marks the lowest quarterly Interest Expenses since Q4 2014.
  • Per Business Quant data, INTI's Interest Expenses in the three quarters before Q4 2022 was $7,705 (Q3 2022), $6,763 (Q2 2022) and $5,410 (Q1 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int Expense (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 217.00 Mn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 462.00 Mn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 435.00 Mn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 269.00 Mn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Inhibitor Therapeutics 13.90 Mn 6.72 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 3,356.00
Sep 30, 2022 7,705.00
Jun 30, 2022 6,763.00
Mar 31, 2022 5,410.00
Dec 31, 2014 950.00
Sep 30, 2014 1,979.00
Jun 30, 2014 24,994.00
Mar 31, 2014 9,558.00
API Access

Inhibitor Therapeutics Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-expenses&ticker=INTI&period=max&api_key=YOUR_API_KEY